Atlas' head start in school

Atlas Venture is leveraging years of purely academic work in gene therapy to launch its most advanced biotech in the firm's recent funds. Avrobio Inc. plans to use last week's $25 million series A round to advance a pair of Phase I candidates as well as to aggregate additional ex vivolentiviral gene therapies from academia.

Atlas, Clarus Ventures and SV Life Sciences co-led the round. The small syndicate is in line with how Atlas plans to deploy its first life science-only fund, which closed at $280 million in April 2015 (see BioCentury, April 20, 2015)...